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ABSTRACT
Objectives: Coenzyme Q10 (CoQ10) deficiency
syndrome is a rare condition that causes mitochondrial
dysfunction and includes a variety of clinical
presentations as encephalomyopathy, ataxia and renal
failure. First, we sought to set up what all have in
common, and then investigate why CoQ10
supplementation reverses the bioenergetics alterations
in cultured cells but not all the cellular phenotypes.
Design Modelling study: This work models the
transcriptome of human CoQ10 deficiency syndrome in
primary fibroblast from patients and study the genetic
response to CoQ10 treatment in these cells.
Setting: Four hospitals and medical centres from
Spain, Italy and the USA, and two research laboratories
from Spain and the USA.
Participants: Primary cells were collected from
patients in the above centres.
Measurements: We characterised by microarray
analysis the expression profile of fibroblasts from
seven CoQ10-deficient patients (three had primary
deficiency and four had a secondary form) and aged-
matched controls, before and after CoQ10
supplementation. Results were validated by Q-RT-PCR.
The profile of DNA (CpG) methylation was evaluated
for a subset of gene with displayed altered expression.
Results: CoQ10-deficient fibroblasts (independently
from the aetiology) showed a common transcriptomic
profile that promotes cell survival by activating cell
cycle and growth, cell stress responses and inhibiting
cell death and immune responses. Energy production
was supported mainly by glycolysis while CoQ10
supplementation restored oxidative phosphorylation.
Expression of genes involved in cell death pathways
was partially restored by treatment, while genes
involved in differentiation, cell cycle and growth were
not affected. Stably demethylated genes were
unaffected by treatment whereas we observed restored
gene expression in either non-methylated genes or
those with an unchanged methylation pattern.
ARTICLE SUMMARY
Article focus
▪ To analyse the common gene expression profile
in primary cell cultures of dermal fibroblasts
from patients suffering any of the clinical presen-
tation of the human syndrome of coenzyme Q10
(CoQ10) deficiency (primary or secondary CoQ10
deficiency).
▪ To determine why CoQ10 treatment, the current
therapy for all forms of CoQ10 deficiency, restored
respiration but not all the clinical phenotypes.
▪ To investigate the stable genetic cause respon-
sible for the survival adaptation to mitochondrial
dysfunction owing to CoQ10 deficiency.
Key messages
▪ The mitochondrial dysfunction owing to CoQ10
deficiency induces a stable survival adaptation of
somatic cells in patients at early or postnatal
development by epigenetic modifications of chro-
matin. Deficient cells unable to maintain this sur-
vival state during differentiation would die
contributing to the pathological phenotype.
▪ Supplementation with CoQ10 restores respiration
through enhanced sugar rather than lipid metab-
olism; partially restores stress response, immun-
ity, cell death and apoptotic pathways; and does
not affect cell cycle, cell growth, and differenti-
ation and development pathways.
▪ Survival transcriptome in the CoQ10 deficiency
syndrome is acquired by epigenetic modifications
of DNA: DNA-demethylated genes corresponded
to unaffected genes by CoQ10 treatment, whereas
those with unchanged DNA-methylation pattern
corresponded to genes with responsive expres-
sion to CoQ10 supplementation. These results
would approach to explain the incomplete recov-
ery of clinical symptoms after CoQ10 treatment, at
least in some patients.
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Conclusions: CoQ10 deficiency induces a specific transcriptomic
profile that promotes cell survival, which is only partially rescued by
CoQ10 supplementation.
INTRODUCTION
Coenzyme Q10 (CoQ10) is a small electron carrier which
is an essential cofactor for several mitochondrial bio-
chemical pathways such as oxidative phosphorylation,
β-oxidation and pyrimidine nucleotide biosynthesis.
CoQ10 biosynthesis depends on a multienzyme complex
1
that involves at least 11 proteins encoded by COQ genes.
Mutations in any of these genes cause primary CoQ10
deﬁciencies, which are clinically heterogeneous mito-
chondrial diseases.2 Clinical presentations include ence-
phalomyopathy with lipid storage myopathy and
myoglobinuria,3 ataxia and cerebellar atrophy,4 severe
infantile encephalomyopathy with renal failure,5 isolated
myopathy,6 and nephrotic syndrome.7 Secondary CoQ10
deﬁciency has also been associated with diverse mito-
chondrial diseases.8–13 In all of these conditions, CoQ10
supplementation partially improves symptoms14 15 and
usually induces a return to normal growth and respir-
ation in CoQ10-deﬁcient ﬁbroblasts.
8 16 17 Adaptation of
somatic cells to CoQ10 deﬁciency may affect both onset
and course of the disease. We document common tran-
scriptomic proﬁle alterations in somatic cells of
CoQ-deﬁcient patients, their response to CoQ10 supple-
mentation, and the relationship with the DNA methyla-
tion status of speciﬁc genes.
MATERIALS AND METHODS
Cells
Primary skin ﬁbroblasts from CoQ10-deﬁcient patients and
from aged-matched controls, at similar culture passage,
were cultured at 37°C using Dulbecco's Modiﬁed Eagle
Medium (DMEM) 1 g/l glucose, L-glutamine and pyruvate
(Invitrogen, Prat de Llobregat, Barcelona) supplemented
with an antibiotic/antimycotic solution (Sigma Chemical
Co, St Louis, Missouri) and 20% fetal bovine serum (FBS,
Linus). When required, CoQ10 prediluted in FBS was
added to the plates at a ﬁnal concentration of 30 µM
(CoQ10, Synthetic Minimum 98%, high-performance
liquid chromatography, Sigma). We studied ﬁve patients
with primary CoQ10 deﬁciency: two siblings harboured a
homozygous p.Y297C mutation in the COQ2 gene,5 other
with a pathogenic mutation (c.483G>C) in the COQ4 gene
(this paper), and another one with haploinsufﬁciency of
COQ4.18 Patients with secondary CoQ10 deﬁciency
included: a mitochondrial encephalopathy, lactic acidosis
and stroke-like episodes patient harbouring the
m.3243A>G in the mitochondrial tRNALeu(UUR) with 43%
heteroplasmy level,8 a patient with mtDNA depletion syn-
drome12 and a third patient with ataxia of unknown
origin.4 Table 1 summarises the clinical phenotype and
biochemical studies of these patients.
Transcriptome analysis
RNA extraction, probe synthesis and hybridisation with
two independent expression arrays (GeneChip Human
Genome U133 Plus 2.0 and GeneChip Human Gene 1.0
ST, Affymetrix) were used as described.19 Gene expres-
sion was validated by the MyiQ Single Color Real Time
PCR Detection System (Biorad). See supplementary
methods for full description.
Data had been deposited with the NCBI-GEO data-
base, at http://www.ncbi.nlm.nih.gov/geo/, accession
number GSE33941 (this SuperSeries is composed of two
subset Series, see online supplementary table S7 for an
explanation).
Statistical analyses were performed comparing each
signal of patient’s ﬁbroblasts RNA with the correspond-
ing signal of control RNA by two different approaches.
The main statistical analysis for both GeneChip Human
Genome U133 Plus 2.0 Array and GeneChip Human
Gene 1.0 ST Array was achieved as previously
described,19 which selects the most signiﬁcant genes
commonly and equally regulated in all samples using
very stringent parameters. In a few special cases, other
unselected but regulated genes were studied because of
their role in speciﬁc processes and pathways. They were
equally described in table 2. The second statistical ana-
lysis approach for the Gene Ontology (GO) study was
performed as previously described20 and analyses the
most altered biological processes and pathways using a
lower stringency analysis, which permits to select the
hundred most altered GOs in different functional cat-
egories (see online supplementary table S4) and the
hundred more distorted pathways (see online
supplementary table S5) that had been regulated in
CoQ10-deﬁcient cells. GO regulated in both independ-
ent analysis of primary and secondary CoQ10 deﬁcien-
cies (see online supplementary table 3), and those
regulated by CoQ10 supplementation (see online
supplementary table S9) were studied using the
GORILLA software (Gene Ontology enrichment analysis
and visualisation tool), at http://cbl-gorilla.cs.technion.
ARTICLE SUMMARY
Strengths and limitations of this study
▪ Human CoQ10 deficiencies are considered rare diseases with
low prevalence, which limits the sample size.
▪ The genetic heterogeneity of this disease is owing to mutations
in any of the 11 genes directly involved in the synthesis of
CoQ10 inside mitochondria, or other mutations altering
somehow the mitochondria and its metabolism, affecting their
inner CoQ10 synthesis as a side effect, will course with CoQ10
deficiency.
▪ Among this genetic heterogeneity, all cells showed a common
transcriptomic profile that justified their pathological pheno-
type, responded equally to CoQ10 treatment and presented the
same DNA methylation pattern.
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Table 1 Clinical phenotype and biochemical studies performed in patients with coenzyme Q10 deficiency
Patient/cells* Clinical phenotype
Biochemical studies (% with
respect to mean reference
values) Effect of CoQ10 supplementation†
Reference as
cited in the text
Array and
epigenetic code
Human dermal skin
fibroblast
Healthy volunteers Reference values Reference values 12 #2
#HDF
#control
12-year-old girl ▸ Ataxia and cerebellar
atrophy
▸ Secondary CoQ10 deficiency
▸ 17% CoQ10 in muscle
▸ 31% mt-RC complex I+III
(muscle)
▸ 46% mt-RC complex II+III
(muscle)
▸ 22% CoQ10 in fibroblast
▸ 24% CoQ10 biosynthesis rate
▸ ROS production (three fold)
▸ Improvement of neurological
assessment
▸ No biochemical studies performed
4 #1
33-month-old boy(his
sister below)
▸ Corticosteroid-resistant
nephropathy
▸ Progressive
encephalomyopathy
▸ COQ2 gene mutation
(c.890A>G)
▸ Primary CoQ10 deficiency
▸ 23% CoQ10 in muscle
▸ 19% mt-RC complex I+III
(muscle)
▸ 32% mt-RC complex II+III
(muscle)
▸ 17% CoQ10 in fibroblast
▸ 10% CoQ10 biosynthesis rate
▸ 57% mt-RC complex II+III
(cells)
▸ Improvement of neurological
assessment but not the renal
dysfunction
▸ Recovery of cell growth
▸ Improvement of 35% complex II+III
(cells)
5
17
12 case 3
#3
9-month-old girl(her
brother above)
▸ Corticosteroid-resistant
nephropathy
▸ COQ2 gene mutation
(c.890A>G)
▸ Primary CoQ10 deficiency
▸ 29% CoQ10 in fibroblast
▸ 15% CoQ10 biosynthesis rate
▸ 60% mt-RC complex II+III
(cells)
▸ Improvement of 25% complex II+III
(cells)
▸ Recovery of cell growth
17
12 case 4
#5
Boy ▸ MELAS (A3243G mutation)
▸ Secondary CoQ10 deficiency
▸ 58% CoQ10 in fibroblast
▸ 35% mt-RC complex I (cells)
▸ 41% mt-RC complex II+III
(cells)
▸ 12% mt-RC complex IV (cells)
▸ 60% mt-ΔΨ
▸ 70% mitochondrial mass
▸ ROS production (>2-fold)
▸ Defective autophagosome
elimination
▸ Recovery of mt-RC
▸ Recovery of ATP production
▸ No ROS production
8 #4
#MEL+Q
Continued
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Table 1 Continued
Patient/cells* Clinical phenotype
Biochemical studies (% with
respect to mean reference
values) Effect of CoQ10 supplementation†
Reference as
cited in the text
Array and
epigenetic code
10-day-old boy ▸ mtDNA depletion syndrome
▸ Neonatal encephalopathy
▸ Secondary CoQ10 deficiency
▸ 20% CoQ10 in muscle
▸ 32% mt-RC complex I+III
(muscle)
▸ 19% mt-RC complex II+III
(muscle)
▸ 15% CoQ10 in fibroblast
▸ 85% mt-RC complex II+III
(cells)
▸ Improvement of 41% complex II+III
(cells)
▸ Recovery of cell growth
34 #ELO
#ELO+Q
3-year-old boy ▸ Dysmorphic features
▸ Ventricular septal defect and
weakness
▸ Hypotonia and hyporeactivity
▸ Moderate mental retardation
▸ COQ4 gene deletion
▸ Primary CoQ10 deficiency
▸ 40% CoQ10 in fibroblast
▸ 44% CoQ10 biosynthesis rate
▸ 64% mt-RC complex I+III (cells)
▸ 58% mt-RC complex II+III
(cells)
▸ Improvement in muscle tone and
strength
▸ He began to speak and walk
18 #GIO
Girl ▸ COQ4 gene mutation
(c.483G>C)
▸ Rhabdomyolysis
▸ Primary CoQ10 deficiency
▸ 18% CoQ10 in fibroblast ▸ Recovery of both complex I+III
activity and growth of fibroblasts
This paper #SIL+Q#epi
Girl ▸ Ataxia
▸ Secondary CoQ10 deficiency
▸ 38% CoQ10 in fibroblast ▸ Improvement of ATP synthesis
12 case 1 #SOF+Q#epi
*Cultured at 37°C using DMEM 1 g/l glucose, L-glutamine, pyruvate (Invitrogen) plus antibiotic/antimycotic solution (Sigma) and 20% fetal bovine serum (FBS, Linus).
†CoQ10 prediluted in FBS was added to the plates at a final concentration of 30 µM (coenzyme Q10, Synthetic Minimum 98%, high-performance liquid chromatography, Sigma).
CoQ10, Coenzyme Q10; MELAS, mitochondrial encephalopathy, lactic acidosis and stroke-like episodes; mtDNA, mitochondrial DNA; mt-RC, mitochondrial respiratory chain; ROS, reactive
oxygen species.
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Table 2 Differentially expressed genes in coenzyme Q10 deficiency
Gene symbol* Gene title FC† FC‡ CoQ10§ Q-RT-PCR¶ CoQ10**
Mitochondrial metabolism
C7orf55 Chromosome 7 open reading frame 55 −2.1 nc –
BRP44 Brain protein 44 2.0 2.3 U 8.0 –2-fold
C10orf58 Chromosome 10 open reading frame 58 −19.5 −1.6 pR
NADH mobilisation
CYB561 Cytochrome b561 −1.3 nc O
CYB5A Cytochrome b5-A −1.4 −1.5 U
CYB5R1 Cytochrome b5 reductase 1 −1.3 nc U
CYB5R2 Cytochrome b5 reductase 2 −1.4 −1.9 U
CYB5R3 Cytochrome b5 reductase 3 −1.4 −1.6 R
CYB5R4 Cytochrome b5 reductase 4 −1.3 −1.6 R
Lipid metabolism
FDFT1 Farnesyl-diphosphate farnesyltransferase 1 −2.3 −1.5 U −4.3 +2-fold
IDI1 Isopentenyl-diphosphate δ isomerase 1 −2.1 nc U
CH25H Cholesterol 25-hydroxylase −10.8 −3.2 O −1.3 –3-fold
RSAD2 Radical S-adenosyl methionine domain containing 2 −6.8 1.4 pR
INSIG1 Insulin-induced gene 1 −2.6 1.7 O
LDLR Low density lipoprotein receptor −3.0 −1.8 pR
SQLE Squalene epoxidase −2.5 nc U
SCD Stearoyl-coenzyme A desaturase (δ-9-desaturase) −3.3 nc U
Insulin metabolism
CPE Carboxypeptidase E 10.0 2.5 pR
PAPPA Pregnancy-associated plasma protein A, pappalysin 2.5 1.7 R 4.8 –5-fold
PCSK2 Proprotein convertase subtilisin/kexin type 2 −75.5 −4.3 O
Other metabolism
SCIN Scinderin −5.4 −1.4 O
PYGL Phosphorylase, glycogen; liver −2.5 −1.6 R
SLC40A1 Solute carrier family 40 (iron-regulated transporter) 7.6 2.9 R
QPRT Quinolinate phosphoribosyltransferase −3.4 nc R
ATP8B1 ATPase, class I, type 8B and member 1 2.4 nc pR
Cell cycle
POSTN Periostin, osteoblast specific factor 73.8 153.9 U 238.2 –20%
VEGFA Vascular endothelial growth factor A 2.9 nc –
SEMA5A Semaphorin 5A, receptor for cell growth 3.6 1.6 pR
AEBP1 AE binding protein 1 66.1 nc R
CSRP2 Cysteine and glycine-rich protein 2 5.3 1.5 R
DOK5 Docking protein 5 6.5 1.6 U
MID1 Midline 1 (Opitz/BBB syndrome) 3.9 4.4 U
CHURC1 Churchill domain containing 1 3.5 nc –
CREG1 Repressor 1 of E1A-stimulated genes 3.0 1.3 R
RUNX1 Runt-related transcription factor 1 (aml1 oncogene) 1.9 1.6 –
BHLHB5 Basic helix-loop-helix domain containing; class B, 5 −6.1 −1.4 –
IFITM1 Interferon induced transmembrane protein 1 (9–27) −3.8 −3.7 O
EDN1 Endothelin 1 −3.0 nc U
MATN2 Matrilin 2 −9.2 nc U
MCAM Melanoma cell adhesion molecule −6.7 −3.0 R −10.9 +10%
MKX Mohawk homeobox −4.5 −1.5 –
PSG6 Pregnancy specific β-1-glycoprotein 6 2.6 nc –
DCN Decorin 2.0 −1.6 –
PKP4 Plakophilin 4 2.0 1.4 U
EFEMP1 EGF-containing fibulin-like extracellular matrix protein 1 13.2 2.2 pR
VCAN Versican 2.8 2.7 – 4.6 +10%
SMARCA1 Component of SWI/SNF chromatin complex, member A1 −1.3 nc pR
SMARCA4 Component of SWI/SNF chromatin complex, member A4 −1.9 nc pR
CDK6 Cyclin-dependent kinase 6, overexpressed in tumour 1.4 2.9 U
CDKN1A P21, inhibitor of CDK −9.2 −2.1 U
CDKN1C P57, inhibitor of CDK −2.6 −1.3 R
CDKN3 Inhibitor of CDK, overexpressed in cancer cells 1.9 2.7 U
Continued
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Table 2 Continued
Gene symbol* Gene title FC† FC‡ CoQ10§ Q-RT-PCR¶ CoQ10**
CD31 Cell surface antigen −1.8 −1.5 R
RB1 Retinoblastoma protein −1.4 nc R
E2F7 E2F transcription factor 7 3.6 nc U
E2F8 E2F transcription factor 8 2.2 nc U
FST Follistatin 2.6 1.4 O
Development and differentiation
BDNF Brain-derived neurotrophic factor −2.9 nc pR
GRP Gastrin-releasing peptide −263.6 nc –
NTNG1 Netrin G1 −8.3 1.8 U
PTN Pleiotrophin (neurite growth-promoting factor 1) −2.7 nc R
FOXQ1 Forkhead box Q1 −6.5 nc –
HOXA11 Homeobox A11 −4.3 −2.4 U
HOXC9 Homeobox C9 −4.8 −2.0 U
LHX9 LIM homeobox 9 −93.0 −1.5 U
SP110 SP110 nuclear body protein −2.5 nc pR
P2RY5 Purinergic receptor P2Y; G-protein coupled, 5 −4.4 −1.3 pR
TSPAN10 Tetraspanin 10 −10.1 nc –
EPSTI1 Epithelial stromal interaction 1 −5.2 −1.4 R
TSHZ1 Teashirt zinc finger homeobox 1 −2.8 nc R
KRT34 Keratin 34 −5.3 −7.6 R −5.7 –60%
TPM1 Tropomyosin 1 (α) −1.8 1.7 –
FOXP1 Forkhead box P1 2.3 nc –
LMCD1 LIM and cysteine-rich domains 1 3.8 nc U
Cell resistance to stress
CYP1B1 Cytochrome P450, family 1B and polypeptide 1 4.5 1.5 – 7.0 –5-fold
MGC87042 Similar to six epithelial antigen of prostate 12.2 – R
TMEM49 Transmembrane protein 49/microRNA 21 1.9 nc –
RAD23B RAD23 homologue B (Saccharomyces cerevisiae) 2.2 nc R
TXNIP Thioredoxin-interacting protein 2.0 −4.9 –
SGK1 Serum/glucocorticoid regulated kinase 1 3.4 1.5 –
SOCS3 Suppressor of cytokine signalling 3 −3.6 nc R
RHOU Ras homologue gene family. member U −8.3 nc O
Apoptosis
AIM1 Absent in melanoma 1 −4.5 −1.4 O
APCDD1 Adenomatosis polyposis coli down-regulated 1 −6.4 −1.8 O
MAGED1 Melanoma antigen family D, 1 −1.7 nc U
MAGED4/4B Melanoma antigen family D, 4/4B −5.0 −1.6 U
RAC2 Small GTP-binding protein Rac2 (rho family) −2.3 −1.3 U
TRIM55 Tripartite motif-containing 55 −11.7 −1.6 U
IFI6 Interferon, α-inducible protein 6 −4.9 −1.3 R
XAF1 XIAP associated factor-1 −3.0 −1.5 R
TNFRSF10D Tumour necrosis factor receptor superfamily 10D 2.4 2.6 U 15.1 +20%
SFRP1 Secreted frizzled-related protein 1 8.7 2.5 U 11.8 –2-fold
Signalling
ARL4C ADP-ribosylation factor-like 4C 3.8 1.6 pR
USP53 Ubiquitin specific peptidase 53 4.2 1.7 –
GABBR2 γ-aminobutyric acid B receptor, 2 13.8 2.0 U
CNGA3 Cyclic nucleotide gated channel α-3 −67.3 nc –
GNG2 G-protein, γ-2 −4.2 1.4 pR
HERC6 Hect domain and RLD 6 −7.4 −1.4 R
MLPH Melanophilin −8.5 −1.9 R
NCK2 NCK adaptor protein 2 −1.7 nc –
PARP14 Poly (ADP-ribose) polymerase family, member 14 −3.1 −1.5 –
Immunity
CDC42SE2 CDC42 small effector 2 −2.8 nc –
LY6K Lymphocyte antigen 6 complex, locus K −4.7 1.4 –
GALNAC4S-
6ST
B cell RAG associated protein −17.3 −2.5 O
Continued
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ac.il/.21 Full description of statistical analysis be found in
the supplementary material.
Epigenetic analysis
DNA (CpG) methylation analysis was performed using a
base-speciﬁc cleavage reaction with bisulﬁte combined
with mass spectrometric analysis (MassCLEAVE). For
the statistical analysis, the CpGs’ methylation degree
for each gene was analysed with the MultiExperiment
Viewer software developed by Saeed.22 See supplemen-
tary methods for full description.
RESULTS
Transcriptome analysis
We studied skin ﬁbroblasts from four patients with
primary CoQ10 deﬁciency and three patients with sec-
ondary CoQ10 deﬁciency (table 1). We analysed the tran-
scriptomic proﬁles and compared them with those of
cells from age-matched control individuals, and evalu-
ated the modiﬁcations induced by supplementation with
30 μM CoQ10 for 1 week to allow recovery of ATP
levels.8 16 17 A very stringent analysis selected the most
signiﬁcant genes displaying a common and equally
altered expression in all samples (summarised in table 2
and shown with full details in online supplementary
table S1). Other genes unselected by this analysis, but
still abnormally expressed were also included in the
study because of their role in speciﬁc processes and
pathways, such as NADH mobilisation, cell cycle and
immunity (see online supplementary table S1) and ener-
getic metabolism (see online supplementary table S2).
GO classiﬁcation of these genes showed similar
proﬁles when comparing independently primary-
deﬁcient and secondary-deﬁcient ﬁbroblasts (see online
supplementary table S3). A lower stringency analysis
showing the most altered biological processes and path-
ways selected 100 most altered GO in different func-
tional categories (see online supplementary table S4)
and 100 more distorted pathways (see online
supplementary table S5) in CoQ10-deﬁcient cells. See
supplementary data for description of statistical analyses.
CoQ10 treatment modiﬁed the speciﬁc transcriptomic
proﬁle displayed by CoQ10-deﬁcient ﬁbroblasts (see
Table 2 Continued
Gene symbol* Gene title FC† FC‡ CoQ10§ Q-RT-PCR¶ CoQ10**
TNFSF4 Tumour necrosis factor superfamily, member 4 −5.9 nc –
TRIM14 Tripartite motif-containing 14 −4.5 nc –
BTN3(A2/A3) Butyrophilin 3 (A2/A3) −2.0 −1.3 R
IFI27 Interferon, α-inducible protein 27 −9.8 nc O
IFI44 Interferon-induced protein 44 −3.3 −2.3 R
IFI44L Interferon-induced protein 44-like −15.0 −1.9 R
IFIT1 Interferon-induced protein (tetratricopeptide repeats 1) −5.3 nc –
IFIT3 Interferon-induced protein (tetratricopeptide repeats 3) −3.5 −1.7 R
GBP1 Guanylate binding protein 1, interferon-inducible −2.7 – –
ISG15 ISG15 ubiquitin-like modifier −6.4 nc R
MX1 Myxovirus resistance 1 −7.4 −1.8 pR
MX2 Myxovirus resistance 2 −6.1 −3.0 pR
OAS1 20,50-oligoadenylate synthetase 1, 40/46 kDa −5.1 −4.9 R
OAS2 20-50-oligoadenylate synthetase 2, 69/71 kDa −6.2 −1.6 R
OAS3 20-50-oligoadenylate synthetase 3, 100 kDa −3.6 −1.3 R
OASL 20-50-oligoadenylate synthetase-like −3.1 −2.6 R
PSMB9 Proteasome subunit, β-type, 9 −1.8 nc U
*In italic letter, biomarkers used in several types of cancer as described by Yoo and collaborators.28 See the text for more information.
†Full change (FC) in the comparative analysis ran with Affymetrix GeneChip Human Genome U133 Plus 2.0 Array. Values represent the FC
(mean) for each gene corresponding to different patient samples (SAM analysis; R=1.5; false discovery rate (FDR)=0%). In parenthesis, FC of
non-significant genes by the statistical threshold used, which were selected owing to their role in specific processes and pathways (see the
text for full details). In the case of different probes selected for one gene, values represent the mean of FC for each probe (see online
supplementary table S1 for full details).
‡FC in the comparative analysis ran with Affymetrix Gene Chip Human Gene 1.0 ST Array. In parenthesis, FC of non-significant genes by the
statistical threshold used. Genes with no change (nc).
§Effect of coenzyme Q10 (CoQ10) supplementation on gene expression in CoQ10 deficiency: unaffected genes by CoQ10 treatment (U); genes
that restored the expression either partially (pR) or completely (R); genes with opposite regulation than in CoQ10 deficiency (O); and
specifically regulated genes only after CoQ10 supplementation (S). Genes non-affected by CoQ10 supplementation (−). See the text and
online supplementary table S8 for full details.
¶FC in gene expression analysed by quantitative real time PCR (Q-RT-PCR). See supplementary material and table S11 for primer
sequence.
**Effect of CoQ10 supplementation on mRNA levels analysed by Q-RT-PCR. Positive values, increase on gene expression; negative values,
decrease on gene expression.
AE binding protein 1, adipocyte enhancer binding protein 1; aml1 oncogene, acute myeloid leukaemia 1 oncogene; EGF-containing fibulin-like
extracellular matrix protein 1, elongation factor G-containing fibulin-like extracellular matrix protein 1; small GTP-binding protein Rac2 (rho
family), small guanosine triphosphate-binding protein Rac2 (rho family); SP110 nuclear body protein, specificity protein-110 nuclear body
protein.
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online supplementary tables S6 and S7). We classiﬁed
genes into ﬁve groups according to the consequence of
CoQ10 treatment on gene expression (see online
supplementary table S8 for a graphical view). About
54% of probes with altered expression were unaffected
by CoQ10 supplementation. Only 36% of probes showed
partial or complete normalisation of expression and 2%
showed inverse regulation (ﬁgure 1). Approximately 5%
of probes were speciﬁcally altered after treatment in
both deﬁcient and non-deﬁcient cells and 3% showed
small or non-speciﬁc changes (these were not consid-
ered for further analysis). After statistical analysis, we
obtained 70 altered GO with a signiﬁcant p value
(<0.001) and an enrichment value that represents the
most altered GO within each group (see online
supplementary table S9).
Data have been deposited with the NCBI-GEO data-
base, at http://www.ncbi.nlm.nih.gov/geo/, accession
number GSE33941 (see online supplementary table S10
for an explanation). The functional description of each
gene was updated from the GeneCard of The Human
Gene Compendium (Weizmann Institute of Science),
http://www.genecards.org/. See supplementary data for
a full description of genes, biological process and path-
ways regulated in CoQ10 deﬁciency.
CoQ10-deficient fibroblasts readapt the energetic
metabolism and CoQ10-treatment restores
In CoQ10-deﬁcient ﬁbroblasts, mitochondrial functions,
including respiratory chain and tricarboxylic acid (TCA)
cycle, were repressed, whereas 9 of 10 steps in glycolysis
and pyruvate metabolism were activated, including
lactate and pyruvate dehydrogenases (see online
supplementary tables S2 and S4). Accordingly, genes
involved in the negative regulation of glycolysis were
downregulated, whereas those involved in its activation
were upregulated (see online supplementary table S2).
Furthermore, genes involved in cytosolic NADH oxida-
tion (cytochrome b5 and several oxidoreductases) were
slightly repressed (table 2). The expression of genes
involved in cholesterol and fatty acid metabolism was
downregulated (table 2), as well all the GO related with
lipid metabolism (see online supplementary table S5).
CoQ10 supplementation normalised the expression
(either partially or completely) of genes involved in the
glycolytic pathway and activated the expression of
repressed respiratory chain genes, whereas the TCA
cycle remained unaffected (see online supplementary
table S2). Most of the repressed enzymes of lipid metab-
olism and fatty acid β-oxidation remained downregulated
(table 2), whereas several other pathways, such as mono-
carboxylic acid transport and the insulin response, were
normalised (see online supplementary table S9). These
results are in agreement with the recovery of aerobic
metabolism observed in CoQ10-deﬁcient ﬁbroblasts after
CoQ10 supplementation.
8 16 17
CoQ10 deficiency induces specific adaptations of cells
to promote survival
The major novel ﬁnding of transcriptome proﬁling in
CoQ10-deﬁcient ﬁbroblasts was the altered expression of
genes concerned with cell cycle and development and
with resistance to stress and cell death (table 2). This
suggests both a remodelling of differentiation and
growth maintenance and an increase of cell survival
mechanisms. Speciﬁcally, genes involved in cell cycle
activation and maintenance were upregulated, and
genes involved in cell cycle regulation increased or
decreased their expression depending of their activating
or repressing roles. This proliferative response was also
enhanced by the repression of cellular attachment
factors and by the activation of extracellular matrix pro-
teins that reduce cell attachment and favour cell div-
ision. In parallel, GO clusters favouring cell cycle and
cell division were activated, and those inhibiting cell
growth were repressed (see online supplementary
table S4). The differentiation of these cells was compro-
mised because many required factors, transducers, anti-
gens and structural proteins appeared downregulated,
whereas repressors of differentiation during develop-
ment were overexpressed (table 2). See supplementary
material for a full description of genes, biological pro-
cesses and related pathways.
Figure 1 Cluster of genes differentially expressed in
coenzyme Q10 (CoQ10)-deficiency and after CoQ10
supplementation. Four arrays of two representative fibroblasts
from patients with Q deficiency were plotted with two arrays of
control fibroblasts and nine arrays of five patient’s fibroblasts
with CoQ10 deficiency treated with 30 µM CoQ10. Activated
genes were coloured in red and repressed ones in green.
Between parentheses—group classification of genes after
CoQ10 supplementation (see online supplementary Table S3).
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Cell cycle activation was supported by the upregulation
of CDK6 (table 2), a cyclin-dependent kinase that
induces entry into the S-phase, and by a robust repres-
sion (more than ninefold) of p21/CDKN1A, an inhibi-
tor of cyclin-dependent kinase that blocks cell cycle at
the G1/S check point to stimulate cell differentiation.
Moreover, subsequent pathways inactivated by p2123
were enhanced in CoQ10-deﬁcient cells (see online
supplementary table S5), as well as both transcription
factors E2F7 and E2F8 (table 2), which push the pro-
gression of the cell cycle, activate cell survival and
inhibit apoptosis.24
Cell survival in CoQ10-deﬁcient cells was improved by
the induction of DNA-repairing mechanisms, and by the
establishment of pathways that regulate Jun kinases and
activate NAD(P)H-CoQ oxidoreductase, which are
involved in stress responses (table 2 and see online
supplementary table S4). Components of apoptosis
and cell death pathways were systematically repressed
(table 2), including tumour suppressor genes, antigens,
intracellular mediators and effectors of cell death. Also,
cell surface receptors and modulators that inhibit apop-
tosis were greatly activated.
Interestingly, CoQ10 treatment did not alter the newly
acquired resistance to cell death in CoQ10-deﬁcient
ﬁbroblasts, kept cell growth activated, and allowed a
higher degree of differentiation (tables 2 and see online
supplementary table S8). However, genes controlling
stress resistance pathways and cortical cytoskeleton were
completely restored, as indicated by the shifts in gene
expression listed in table 2. However, treated ﬁbroblasts
kept the DNA repair mechanism activated.
Signalling-related genes and pathways were differen-
tially affected by CoQ10 deﬁciency, but most of
immunity-related genes showed a general downregula-
tion (table 2). Pathways and biological processes
involved in immunity regulation were restored by CoQ10
supplementation (table 2 and see online supplementary
table S5).
Stable DNA methylation profile is responsible for the
specific gene expression profile in CoQ10 deficiency
CoQ10 supplementation modiﬁed the expression of
43% of genes that were abnormally expressed in
CoQ10-deﬁcient ﬁbroblasts (see online supplementary
table S8). In the majority of these cases, expression
levels were restored to those of control ﬁbroblasts
(20%), but few showed inverse regulation (2%) and
others were speciﬁcally altered after CoQ10 treatment
in both deﬁcient and non-deﬁcient cells (5%). The
remaining 16% corresponded to partially restored
genes, which slightly alter their expression level without
changing the CoQ10-deﬁcient pattern. These genes
along with the unaffected (54%) constitute 72% of regu-
lated genes in CoQ10 deﬁciency, which were not signiﬁ-
cantly altered after CoQ10 supplementation.
To explain this differential response to respiratory dys-
function, we analysed the DNA-methylation proﬁle of 20
among the most altered genes listed in table 2. These
genes encompass the main biological processes and
pathways affected by CoQ10 deﬁciency (table 3).
Upregulated genes, which were unaffected by CoQ10
supplementation, had less-deﬁned DNA methylation
sites in their promoter regions.
Genes with partial restoration of their expression after
CoQ10 supplementation showed precise methylation and
demethylation proﬁles that may explain their altered
expression during CoQ10 deﬁciency. The methylation
degree of these genes changed after treatment, and may
be responsible for the modulation of expression (table 3).
The patterns of methylation of activated and repressed
genes in CoQ10 deﬁciency that could be normalised by
CoQ10 supplementation, were either unaffected or only
slightly affected by the treatment, and we did not detect
new methylation sites after CoQ10 supplementation.
However, a few genes showed signiﬁcant differences in
the methylation degree after the treatment, which cor-
respond to the partially restored genes that maintain the
speciﬁc expression pattern of untreated CoQ10 deﬁcient
cells at a lower level.
Finally, reviewing the biological processes and molecu-
lar functions of regulated genes in CoQ10 deﬁciency, the
main adaptation for cell survival activated genes by DNA
demethylation, which increased the expression of genes
involved in cell cycle activation, apoptosis inhibition,
and cell stress resistance, meanwhile the undifferenti-
ated state could be owing to gene repression by DNA
methylation, which decreased the expression of genes
involved in cell differentiation. CoQ10 treatment did not
alter the methylation degree of these genes and subse-
quently the expression level was maintained.
DISCUSSION
CoQ10-deficient fibroblasts readapt the energetic
metabolism and CoQ10-treatment restores
CoQ10 is an essential component of the mitochondrial
respiratory chain,1 therefore dysfunctional mitochondria
are a common ﬁnding in both primary CoQ10 deﬁcien-
cies3–7 and secondary forms.8–13 Although each form
presents a speciﬁc clinical phenotype, all these condi-
tions display a substantial reduction of cellular CoQ10
content and deﬁcit in the mitochondrial enzymatic activ-
ities of respiratory chain (table 1). Accordingly to these
results, we have shown here that ﬁbroblasts from patients
with CoQ10 deﬁciency have reorganised their genetic
resources to cope with this mitochondrial dysfunction.
Consistent with the role of CoQ10 in bioenergetics, the
lack of CoQ10 would force the cell to support it mainly
by glycolysis, whereas both mitochondrial lipid metabol-
ism and respiratory chain were repressed (see online
supplementary tables S2 and S4). These ﬁndings,
together with the mild repression of cytosolic enzymes
that oxidise NADH (cytochrome b5 and its oxidoreduc-
tases listed in table 2) could indicate that NADH is
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Table 3 Epigenetic modifications in CoQ10 deficiency owing to DNA (CpG) methylation/demethylation
Demethylations in CoQ10 deficiency Methylations in CoQ10 deficiency
Gene symbol FC* Q-effect† CpGs‡ CpGs§ Degree (C/P)¶ CpGs’ location** CpGs§ Degree (C/P)¶ CpGs’ location** Q-effect††
POSTN 73.8 U 5 (P) 2 (16 fold) 50%/3% Close together (P) 0 – – –
GABBR2 13.8 U 101 (P,I) 5 (40%) 47%/37% Close together (P) 14 (6-fold) 10%/22% Close together (P) –15%
VCAN 2.8 U 58 (P,E,I) 5 (2-fold) 12%/7% Scattered groups 3 (90%) 9%/17% Dispersed (I) –
TNFRSF10D 2.4 U 59 (P,E,I) 27 (2-fold) 60%/25% Scattered groups (P) 0 – – –
FOXP1 2.3 U 85 (I) 11 (2-fold) 57%/32% Scattered groups 2 (3-fold) 7%/19% Close together –
END1 −3.0 U 25 (P) 0 – – 0 – – –
PARP14 −3.1 U 29 (P) 0 – – 3 (3-fold) 5%/19% Dispersed –
CPE 11.6 pR 26 (P,I) 3 (4-fold) 20%/6% Dispersed 0 – – +2-fold
ARL4C 4.2 pR 63 (P,E,I) 5 (90%) 52%/28% Scattered groups 9 (60%) 16%/28% Scattered groups +7%
HOXA11 −4.3 pR 17 (P) 0 – – 8 (4-fold) 5%/20% Close together (P) –3-fold
AEBP1 66.1 R 80 (P,E,I) 8 (25%) 76%/61% Scattered groups 8 (3-fold) 10%/27% Widely dispersed –
CYP1B1 4.7 R 24 (P) 0 – – 0 – – –
CHURC1 3.5 R 20 (P,E,I) 1 (50%) 11%/7% (I) 0 – – –
PYGL −2.5 R 84 (P,E,I) 8 (2-fold) 12%/6% Close together (E) 1 (3-fold) 4%/13% (P) –
XAF1 −3.0 R 25 (P,E,I) 0 – – 0 – – –
EPSTI1 −5.9 R 34 (P,E) 0 – – 7 (2-fold) 27%/37% Scattered groups –
MCAM −7.7 R 74 (P,E,I) 0 – – 0 – – –
MLPH −8.5 R 8 (P) 0 – – 0 – – –
PCSK2 −94.3 O 32 (P) 0 – – 0 – – –
GRP −263.6 O 73 (P,E,I) 20 (two fold) 53%/35% Scattered groups 6 (50%) 28%/35% Close together (P) –
*Full change (FC) in coenzyme Q10 (CoQ10) deficiency (patient samples (SAM) analysis; R=1.5; false discovery rate (FDR)=0%) ran with Affymetrix GeneChip Human Genome U133 Plus
2.0 Array. Full details are shown in table 2.
†Effect of CoQ10 supplementation on gene expression in CoQ10 deficiency ( for more information see online supplementary table S8): unaffected genes by CoQ10 treatment (U), genes that
restored the expression either partial (pR) or completely (R) and genes with opposite regulation after CoQ10 supplementation than in CoQ10 deficiency (O).
‡Number of CpG islands analysed. In parenthesis, gene location of CpG islands: promoter (P), first exon (E) and first intron (I).
§Significant methylated CpGs for each gene in control and CoQ10-deficient fibroblast. Significance determined by t test (p<0.01). In parenthesis, fold change in methylation degree (small
changes, in %). Non-significant changes in methylation (−).
¶Methylation degree (mean of significant CpG). Values represent the % of CpG’s methylation of both control (C) and patient deficient in CoQ10 (P).
**Location of significant CpGs. In parenthesis, gene location: promoter (P), first exon (E) and first intron (I).
††Significant changes in CpG methylation owing to CoQ10 supplementation in CoQ10 deficiency. Positive values, an increase in the methylation degree and negative values, demethylations.
Significance determined by t test (p<0.01) between CoQ10-supplemented fibroblasts and untreated CoQ10-deficient fibroblasts. Non-significant changes in methylation (−).
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mainly used for biosynthetic purposes rather than for
energy production.
Supplementation with CoQ10, the current therapy for
all forms of CoQ10 deﬁciency, restored respiration
through enhanced sugar utilisation, but did not stimulate
lipid metabolism. The expression of genes involved in
the glycolytic pathway was partially or completely normal-
ised after CoQ10 treatment, whereas the repressed genes
involved in the respiratory chain were activated. The TCA
cycle remained unaffected (see online supplementary
table S2). These results are in agreement with the recov-
ery of aerobic metabolism observed in CoQ10-deﬁcient
ﬁbroblasts after CoQ10 supplementation.
8 16 17
CoQ10 deficiency induces a stable survival
adaptation of cells
CoQ10-deﬁcient ﬁbroblasts adapted several physiological
processes to acquire a cellular-resistance state for survival
under the conditions of mitochondrial dysfunction
induced by CoQ10 deﬁciency. The new genetic pattern
increases cell survival by activating cell cycle and growth,
maintaining an undifferentiated phenotype, upregulat-
ing stress-induced proteins and inhibiting apoptosis and
cell death pathways. These results recapitulate a survival
network that can be observed in nutritional stress such
as when cells are grown in galactose-enriched media.25
The survival adaptation shown by CoQ10-deﬁcient cells
included a global resistance mechanism that is observed
also during the initial phase of tumorigenesis. In fact,
the CoQ10-deﬁcient expression proﬁle was very similar to
that described during myeloid cell transformation26 and
breast tumours.27 Moreover, some of the regulated genes
in CoQ10 deﬁciency (listed in table 2 as italicised letter)
are used as biomarkers in several types of cancer,28 like
KRT34, the cell cycle-related POSTN, MCAM, EFEMP1
and VCAN, and the apoptotic and cell resistance-related
CYP1B1, XAF1 and TNFRSF10D. Although these bio-
markers behaved in CoQ10 deﬁciency (increased or
decreased) as described by Yoo et al,28 there is no sign of
tumour formation reported in the patients so far. In
addition, cellular senescence, a deﬁning feature of pre-
malignant tumours,29 is characterised by a gene expres-
sion pattern similar to that of CoQ10-deﬁcient ﬁbroblasts
(see online supplementary table S5).
Supplementation with CoQ10 enhanced both stress
response and immunity pathways. Although the pathway
of cell death was partially restored, cell cycle and
growth, and the mechanisms to prevent differentiation
and development were not. These results indicate that
the mitochondrial dysfunction owing to CoQ10 deﬁ-
ciency induces a stable survival adaptation of somatic
cells in patients at early or postnatal development, and
we speculate that cells unable to institute, or to main-
tain, this survival mechanism during differentiation will
die, contributing to the pathological phenotype.
A stable DNA methylation profile is responsible of specific
gene expression in CoQ10 deficiency
The cellular adaptation to CoQ10 deﬁciency-enhanced
DNA demethylation of genes that regulate cell cycle acti-
vation, apoptosis inhibition and cell stress resistance as
part of an adaptation survival mechanism. Comparable
results were observed in several models of epigenetic
regulation by demethylation (see online supplementary
table S5), whereas DNA methylation inhibits activation
of genes related to tumorogenesis and apoptosis.30
Pathways unaffected by CoQ10 treatment corresponded
to stably demethylated genes, whereas those that
responded to CoQ10 supplementation were controlled
by genes with unchanged methylation patterns.
We did not ﬁnd changes in the methylation degree of
all genes affected by CoQ10 deﬁciency, suggesting that
other modalities of gene regulation are responsible,
including epigenetic mechanisms such as histone modi-
ﬁcations by methylation and acetylation, or even DNA
methylation in CpG islands other than those studied
here. Interestingly, it has been reported that CoQ10 regu-
lates lipid metabolism in mice liver without any effect on
the DNA methylation proﬁle,31 indicating that supple-
mented CoQ10 by itself may not alter the DNA methyla-
tion pattern that cells acquired during the survival
adaptation to CoQ10 deﬁciency.
Mechanisms unaffected by therapy corresponded to
stably DNA demethylated genes, which were responsible
for the acquisition of the undifferentiated state for sur-
vival and resistance that cells obtain during the adapta-
tion to CoQ10 deﬁciency, whereas the responsive to
CoQ10 supplementation were controlled by genes with
unchanged methylation patterns and correspond mainly
to metabolic genes and those related with the restor-
ation of mitochondrial function.
We propose that these epigenetic changes may be
established as early as during the fetal life32 in order to
cope with CoQ10 deﬁciency; these cells then maintain
this adaptive response throughout their life. We specu-
late that cells unable to maintain this survival mechan-
ism during differentiation would die contributing to the
pathological phenotype.
Our model has some limits: we treated cells only for
1 week and in principle we cannot rule out that pro-
longed exposure to CoQ10 could restore also some of
the other unaffected pathways. Alternatively, incomplete
recovery of the gene expression proﬁles could be
explained by the fact that exogenous CoQ10 can rescue
the bioenergetic defect, but not all other functions
of CoQ10 in these cells, as it has been observed in
other organisms.33
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